TG Therapeutics to Host Conference Call on Third Quarter 2025 Financial Results and Business Update

Rhea-AI Summary

TG Therapeutics (NASDAQ:TGTX) will hold a conference call on Monday, November 3, 2025 at 8:30 AM ET to discuss third quarter 2025 financial results and provide a business outlook for the remainder of 2025.

Michael S. Weiss, Chairman and CEO, will host. The company will issue a press release with financial results prior to the call. Investors can join by phone (1-877-407-8029 U.S.; 1-201-689-8029 outside the U.S.) or listen via a live webcast on the Investors & Media Events page at www.tgtherapeutics.com. An audio replay will be available on the company website for 30 days after the call.

Conference Call to be Held Monday, November 3, 2025, at 8:30 am ET

NEW YORK, Oct. 31, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held, Monday, November 3, 2025, at 8:30 AM ET to discuss results for the third quarter of 2025 and provide a business outlook for the remainder of 2025. Michael S. Weiss, Chairman and Chief Executive Officer, will host the call.

In order to participate in the conference call, please call 1-877-407-8029 (U.S.), 1-201-689-8029 (outside the U.S.), Conference Title: TG Therapeutics Earnings Call. A live webcast of this presentation will be available on the Events page, located within the Investors & Media section, of the Company's website at www.tgtherapeutics.com. An audio recording of the conference call will also be available for replay at www.tgtherapeutics.com, for a period of 30 days after the call.

TG Therapeutics will announce its financial results for this period in a press release to be issued prior to the call.

ABOUT TG THERAPEUTICS 
TG Therapeutics is a fully integrated, commercial stage, biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. In addition to a research pipeline including several investigational medicines, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI® (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features. For more information, visit www.tgtherapeutics.com, and follow us on X (formerly Twitter) @TGTherapeutics and on LinkedIn. 
 
BRIUMVI® is a registered trademark of TG Therapeutics, Inc. 

CONTACT:

Investor Relations
Email: ir@tgtxinc.com
Telephone: 1.877.575.TGTX (8489), Option 4

Media Relations:
Email: media@tgtxinc.com
Telephone: 1.877.575.TGTX (8489), Option 6

FAQ

When is TG Therapeutics' (TGTX) Q3 2025 earnings call scheduled?

The call is scheduled for Monday, November 3, 2025 at 8:30 AM ET.

How can I listen to TG Therapeutics (TGTX) Q3 2025 earnings call?

Call 1-877-407-8029 (U.S.) or 1-201-689-8029 (outside U.S.), or access the live webcast on the company's Investors & Media Events page.

Who will host TG Therapeutics' (TGTX) third quarter 2025 call?

Michael S. Weiss, Chairman and Chief Executive Officer, will host the call.

Will TG Therapeutics (TGTX) release financial results before the Q3 2025 call?

Yes, the company will issue a press release with financial results prior to the call.

How long will the TG Therapeutics (TGTX) earnings call replay remain available?

An audio replay will be available on www.tgtherapeutics.com for 30 days after the call.